Current liquid biopsy diagnostics, and novel uses such as MRD and Molecular Response analysis, are limited by the amount of ctDNA in a typical patients plasma. ctDNA levels vary across indications (Bettegowda 2014) and generally increase with disease stage. ctDNA is released by tumor cell turnover […]
I thought I’d share my roundup of recent reviews that highlight the opportunities, challenges and current state-of-the-art in MRD analysis for solid tumours…enjoy! Moding 2021 (Cancer Discov.): Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease a review from Ash Alizadeh and Max […]
Many of my followers in the cancer space, especially the Hemes folks, will already understand what MRD is and why it’s important. But for those of you who don’t know I thought an explainer might be helpful. I took inspiration from Keiths COVID qPCR explainer and this […]
A new paper from Nitzan Rosenfeld’s group at CRUK-CI (my old stomping ground) reports astounding sensitivity for ctDNA liquid biopsy. In “ctDNA monitoring using patient-specific sequencing and integration of variant reads” Jonathan Wan and his co-authors performed whole exome sequencing on tumour biopsies (and PBMCs) […]
Avida Biomed are an early startup who have developed a novel targeted methylation sequencing technology: Point-n-Seq, for cancer early-detection. Point-n-Seq uses targeted methylation sequencing, which performs enrichment of target molecules directly from cfDNA before bisulfite conversion and amplification. Target panels are small 1-1000 markers. The […]
